Vaccine-focused Valneva consolidates R&D footprint by shuttering site, eliminating 30 roles
French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. The biopharma is shuttering its location in Nantes, a spot…